NeurAxis is a growth stage company focused on developing neuromodulation therapies to address chronic and debilitating conditions in children. NeurAxis is dedicated to advancing the science with its’ proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. We believe that superior science, evidence-based research, and building on its unparalleled body of clinical evidence is necessary for adoption by the medical...
NeurAxis, Inc News
Minot Light Capital Partners, an investment management company, released its “Capital Appreciation Fund” Q1 2026 Investor Letter. A copy of the letter can b...
NRXS' first-quarter 2026 results show surging revenue and expanding gross margin as reimbursement improves under the Category I CPT code....
Neuraxis Inc (NRXS) reports significant revenue growth and strategic expansions, while navigating insurance coverage hurdles and financial adjustments....
Conference call will be held today, Tuesday, May 12 at 9:00 am ETCARMEL, Ind., May 12, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Compan...
CARMEL, Ind., May 05, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commerc...
Alphabet, Walmart and Micron lead Zacks research as AI growth, retail strength and memory demand drive performance, while risks linger....
Alphabet rides AI-driven growth across Search, Cloud and subscriptions, but rising spending, debt and legal risks temper near-term flexibility....
CARMEL, Ind., April 22, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis” or the “Company”) (NYSE American: NRXS), a medical technology company commer...
CARMEL, Ind., April 10, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company comme...
Disclaimer: